MODTX.ST
Modus Therapeutics Holding AB (publ) [MODTX.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
MODTX.ST Stock Summary
Top 10 Correlated ETFs
MODTX.ST
Top 10 Correlated Stocks
MODTX.ST
In the News
MODTX.ST Financial details
Company Rating
Neutral
Market Cap
37.38M
Income
-29.51M
Revenue
0
Book val./share
0.78
Cash/share
0.84
Dividend
-
Dividend %
-
Employees
2
Optionable
No
Shortable
Yes
Earnings
22 Nov 2022
P/E
-0.99
Forward P/E
-
PEG
-0.18
P/S
-
P/B
-2.11
P/C
1.22
P/FCF
-3.55
Quick Ratio
0.18
Current Ratio
0.24
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.76
EPS next Y
-
EPS next Q
-
EPS this Y
-11.4%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-5.26%
-
-
-
-
SMA20
-
SMA50
-50%
SMA100
-50%
Inst Own
-
Inst Trans
-
ROA
-658%
ROE
340%
ROC
0.62%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.01-3.6
52W High
-65.83%
52W Low
+2.5%
RSI
28
Rel Volume
3.36
Avg Volume
25.93K
Volume
87.13K
Perf Week
-3.3%
Perf Month
-29.31%
Perf Quarter
-49.75%
Perf Half Y
-51.88%
-
-
-
-
Beta
0.41
-
-
Volatility
0.02%, 0.11%
Prev Close
0.49%
Price
1.025
Change
15.95%
MODTX.ST Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -2.71 | -0.37 | -1.67 | -1.14 | -1.01 | |
| Operating cash flow per share | -2.73 | -0.45 | -1.3 | -1.35 | 0 | |
| Free cash flow per share | -2.73 | -0.45 | -1.3 | -1.35 | 0 | |
| Cash per share | 0.09 | 0.46 | 1.67 | 0.65 | 1.07 | |
| Book value per share | -0.17 | 0.43 | 1.27 | -0.16 | 1 | |
| Tangible book value per share | -0.17 | 0.43 | 1.27 | -0.16 | 1 | |
| Share holders equity per share | -0.17 | 0.43 | 1.27 | -0.16 | 1 | |
| Interest debt per share | 0.16 | 0 | 0 | 0.73 | 0.08 | |
| Market cap | 84.53M | 84.53M | 47.03M | 44.92M | 30.88M | |
| Enterprise value | 85.69M | 77.21M | 26.38M | 46M | 11.82M | |
| P/E ratio | -1.94 | -14.05 | -2.27 | -2.45 | -1.73 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -1.93 | -11.69 | -2.93 | -2.07 | 0 | |
| PFCF ratio | -1.92 | -11.69 | -2.93 | -2.07 | 0 | |
| P/B Ratio | -31.47 | 12.08 | 2.99 | -17.38 | 1.75 | |
| PTB ratio | -31.47 | 12.08 | 2.99 | -17.38 | 1.75 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -1.97 | -12.83 | -1.28 | -2.55 | -0.72 | |
| EV to operating cash flow | -1.95 | -10.68 | -1.64 | -2.12 | 0 | |
| EV to free cash flow | -1.95 | -10.68 | -1.64 | -2.12 | 0 | |
| Earnings yield | -0.52 | -0.07 | -0.44 | -0.41 | -0.58 | |
| Free cash flow yield | -0.52 | -0.09 | -0.34 | -0.48 | 0 | |
| Debt to equity | -0.95 | 0 | 0 | -4.45 | 0 | |
| Debt to assets | 1.24 | 0 | 0 | 1.02 | 0 | |
| Net debt to EBITDA | -0.03 | 1.22 | 1 | -0.06 | 1.17 | |
| Current ratio | 0.43 | 15.1 | 3.87 | 0.81 | 8.47 | |
| Interest coverage | -43.58K | -6.02K | -20.69K | -57.34 | -10.9 | |
| Income quality | 1.01 | 1.2 | 0.78 | 1.21 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 3.19 | 1.91 | 6.92 | 2.03 | 4.76 | |
| ROIC | 298.47 | -0.86 | -1.31 | -2.02 | -0.92 | |
| Return on tangible assets | -21.25 | -0.8 | -0.98 | -1.63 | -0.89 | |
| Graham Net | -0.18 | 0.43 | 1.26 | -0.2 | 0.98 | |
| Working capital | -2.69M | 7M | 15.68M | -2.64M | 17.63M | |
| Tangible asset value | -2.69M | 7M | 15.74M | -2.59M | 17.68M | |
| Net current asset value | -2.69M | 7M | 15.69M | -2.64M | 17.63M | |
| Invested capital | -0.95 | 0 | 0 | -4.45 | 0 | |
| Average receivables | 0 | 410.5K | 319.5K | 361.5K | 580K | |
| Average payables | 0 | 525.5K | 2.3M | 2.92M | 1.34M | |
| Average inventory | 0 | -410.5 | -319.5 | -246.5 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 16.22 | -0.86 | -1.32 | 7.09 | -1.01 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.58 | -1.1 | -0.29 | -0.19 | -0.18 | |
| Operating cash flow per share | -0.51 | -0.39 | -0.27 | -0.18 | 0 | |
| Free cash flow per share | -0.51 | -0.39 | -0.27 | -0.18 | 0 | |
| Cash per share | 0.65 | 0.41 | 0.3 | 0.24 | 0.84 | |
| Book value per share | -0.16 | -0.54 | -0.83 | -1.02 | 0.78 | |
| Tangible book value per share | -0.16 | -0.54 | -0.83 | -1.02 | 0.78 | |
| Share holders equity per share | -0.16 | -0.54 | -0.83 | -1.02 | 0.78 | |
| Interest debt per share | 0.73 | 0.88 | 1.05 | 1.19 | 0.01 | |
| Market cap | 44.92M | 37.35M | 44.6M | 31.88M | 39.37M | |
| Enterprise value | 46M | 44.76M | 56.28M | 46.51M | 20.31M | |
| P/E ratio | -1.2 | -0.53 | -2.37 | -2.58 | -2.42 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -5.48 | -5.9 | -10.45 | -10.79 | 0 | |
| PFCF ratio | -5.48 | -5.9 | -10.45 | -10.79 | 0 | |
| P/B Ratio | -17.38 | -4.33 | -3.35 | -1.94 | 2.23 | |
| PTB ratio | -17.38 | -4.33 | -3.35 | -1.94 | 2.23 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -5.04 | -7.71 | -12.89 | -18.94 | -5.38 | |
| EV to operating cash flow | -5.61 | -7.07 | -13.19 | -15.74 | 0 | |
| EV to free cash flow | -5.61 | -7.07 | -13.19 | -15.74 | 0 | |
| Earnings yield | -0.21 | -0.47 | -0.11 | -0.1 | -0.1 | |
| Free cash flow yield | -0.18 | -0.17 | -0.1 | -0.09 | 0 | |
| Debt to equity | -4.45 | -1.62 | -1.24 | -1.13 | 0 | |
| Debt to assets | 1.02 | 1.9 | 2.94 | 3.5 | 0 | |
| Net debt to EBITDA | -0.12 | -1.28 | -2.68 | -5.96 | 5.05 | |
| Current ratio | 0.81 | 0.46 | 0.29 | 0.24 | 8.47 | |
| Interest coverage | -38.81 | 25.03 | -13.23 | -3.86 | -12.71 | |
| Income quality | 0.9 | 1.09 | 0.98 | 1.2 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.45 | 3.64 | 2.33 | 2.1 | 1.78 | |
| ROIC | -1.02 | 3.16 | -1.37 | -1.18 | -0.21 | |
| Return on tangible assets | -0.83 | -2.4 | -0.84 | -0.59 | -0.2 | |
| Graham Net | -0.2 | -0.55 | -0.84 | -1.04 | 0.77 | |
| Working capital | -2.64M | -8.68M | -13.37M | -16.46M | 17.63M | |
| Tangible asset value | -2.59M | -8.63M | -13.32M | -16.41M | 17.68M | |
| Net current asset value | -2.64M | -8.68M | -13.37M | -16.46M | 17.63M | |
| Invested capital | -4.45 | -1.62 | -1.24 | -1.13 | 0 | |
| Average receivables | 468K | 472K | 724K | 1.05M | 1.15M | |
| Average payables | 882K | 1.07M | 835.5K | 918.5K | 1.13M | |
| Average inventory | -353K | -357 | -724 | -367 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 3.62 | 2.05 | 0.35 | 0.19 | -0.23 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
MODTX.ST Frequently Asked Questions
What is Modus Therapeutics Holding AB (publ) stock symbol ?
Modus Therapeutics Holding AB (publ) is a SE stock and trading under the symbol MODTX.ST
What is Modus Therapeutics Holding AB (publ) stock quote today ?
Modus Therapeutics Holding AB (publ) stock price is $1.025 today.
Is Modus Therapeutics Holding AB (publ) stock public?
Yes, Modus Therapeutics Holding AB (publ) is a publicly traded company.
Company Profile
- Volume Average 25.93K
- Market Capitalization 37.38M
- Employee 2
- CEO Dr. John Öhd M.D., Ph.D.
- Headquarters Stockholm,SE
- IPO Date 2021-07-22
-
Website
https://www.modustx.com 
Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. Its lead product is Sevuparin, a polysaccharide to treat patients with sepsis and septic shock, which is under Phase Ib clinical study. The company was founded in 2011 and is headquartered in Stockholm, Sweden.
